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sion was 13.6 months (95% CI: 10.71–16.49). The most 
common hematological toxicity was neutropenia (no fe-
brile neutropenia), which occurred in 28 patients (48.3%) 
but grade 3–4 in only 8 patients (14%). Alopecia, the most 
common nonhematological toxicity, occurred in 20 
(34.5%) patients, but only 5 patients (8.6%) experienced 
grade 3 alopecia.  Conclusion: The activity of docetaxel 
and gemcitabine in metastatic breast cancer is con-
fi rmed. The promising results of the employed schedule, 
in agreement with other published studies, need to be 
further confi rmed within a phase III study. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 The treatment of metastatic breast cancer (MBC), a 
typically incurable disease, is one of the main active re-
search ﬁ elds for medical oncologists. Between the 1970s 
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 Abstract 
 Objectives: We conducted a multicenter phase II study 
to evaluate the clinical effi cacy, toxicity, and dose inten-
sity of a new weekly schedule of docetaxel and gem-
citabine as fi rst-line treatment of metastatic breast can-
cer patients.  Methods: We enrolled 58 patients, 52% of 
whom had received a previous anthracycline-containing 
chemotherapy. The treatment schedule was: docetaxel 
35 mg/m 2  and gemcitabine 800 mg/m 2   i.v. on days 1, 8, 
15 every 28 days.  Results: All patients were assessable 
for toxicity and 56 for effi cacy. Overall response rate was 
64.3% with 16.1% of complete responses and 48.2% of 
partial responses. Median survival was 22.10 months 
(95% CI: 15.53–28.67) and median time to tumor progres-
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and the mid-1990s, the anthracyclines were the reference 
chemotherapeutic agents in the treatment of this disease 
with an overall response rate (ORR) of 35–50% in ﬁ rst-
line and 25–30% in second-line treatments  [1] . Nonethe-
less, objective tumor responses are usually short-lived, 
median survival does not exceed 25 months and the tox-
icity proﬁ le is not very suitable for patients with advanced 
disease. In the past decade, the introduction of two tax-
anes, paclitaxel and docetaxel, represented an important 
advance in the treatment of MBC. Docetaxel as a single 
agent, in previously untreated patients, provides ORR 
ranging from 40 to 68%  [2, 3] , while in anthracycline-re-
sistant patients, the ORR is 53–57%  [4, 5] . Although ex-
tremely active in terms of ORR, the 3-week schedule of 
docetaxel 100 mg/m 2  as single agent is associated with 
grade 3–4 neutropenia in 90–95% of the cases  [6] . Week-
ly administration of docetaxel, evaluated in phase II stud-
ies  [6–13] , represents an interesting alternative schedule, 
particularly indicated in the metastatic setting, given the 
opportunity to reduce chemotherapy-related toxicity (es-
pecially hematological toxicity) while preserving its high 
activity. 
 Gemcitabine has been shown to be safe and effective 
when used in MBC. As single agent, both in ﬁ rst- and sec-
ond-line treatments, it has been reported to yield a 12–
38% ORR with a good toxicity proﬁ le  [14–17] . Preclinical 
evidence of a synergism between gemcitabine and 
docetaxel on cytotoxicity and apoptosis in breast cancer 
cells was reported  [18] . Due to the activity of the two 
agents, the different mechanism of action, the nonover-
lapping toxicities and the favorable toxicity proﬁ le of the 
weekly schedule, there is a strong rationale to use this drug 
combination for the treatment of MBC patients, with an 
attempt to combine the clinical response with the im-
provement or maintenance of quality of life and prolon-
gation of survival. We have recently carried out a dose-
ﬁ nding study with docetaxel plus gemcitabine on a new 
weekly schedule (gemcitabine 800 mg/m 2  on days 1, 8 and 
15 every 28 days + docetaxel at 3 escalating dose levels 
of 30, 35 and 40 mg/m 2 ) in 18 pretreated MBC patients 
with the aim to determine the maximum tolerable dose 
(MTD) of docetaxel and the toxicity patterns of this regi-
men. The MTD for docetaxel was established at 35 mg/m 2 . 
Hematological and nonhematological toxicities were low 
in number and manageable  [19] . With this background, 
we conducted a multi-institutional phase II study, whose 
data were partially presented in an abstract form  [20] , to 
evaluate the clinical efﬁ cacy, the toxicity pattern and the 
dose-intensity of a new weekly regimen of docetaxel and 
gemcitabine. 
 Patients and Methods 
 Patients with cytologically and histologically conﬁ rmed breast 
carcinoma at the ﬁ rst diagnosis of metastatic disease were enrolled. 
The presence of measurable disease was requested. Previous hor-
mone therapy for both adjuvant and anti-metastatic purposes was 
allowed. Previous adjuvant radiotherapy or for advanced breast 
cancer was permitted, provided the irradiated lesions were not the 
only site of disease. With regard to adjuvant chemotherapy, if it did 
not include a taxane, patients could be enrolled independently of 
the length of time elapsed from the end of adjuvant therapy; if the 
adjuvant treatment included a taxane, a 12-month interval at the 
end of chemotherapy was mandatory. To be eligible, patients had 
to be aged between 18 and 75 years, have a performance status be-
tween 0 and 2 on the ECOG scale and a life expectancy of more 
than 3 months. Other inclusion criteria included: adequate bone 
marrow [absolute neutrophil count (ANC)  6 1,500/  l, platelet 
count  6 120,000/  l, Hb  6 10 g/dl], liver (serum total bilirubin 
 ^  2 mg/dl; GOT/GPT  ! 2 ! the upper normal value) and renal 
functions (serum creatinine  ^  1.2 mg/dl); absence of other concur-
rent or previous malignant neoplasm, with the exception of ade-
quately controlled in situ uterine carcinoma and/or cutaneous bas-
al cell carcinoma; geographical accessibility to the participating 
oncology centers and written informed consent. Exclusion criteria: 
clinically detectable brain metastases, concurrent and uncontrolled 
cardiovascular, metabolic, renal, neurological or infectious diseas-
es. Previous chemotherapy for metastatic disease, concurrent treat-
ment with other chemotherapeutic, hormonal or immunological 
antineoplastic agents, and pregnancy also rendered the patient in-
eligible. The study was approved by an independent ethics com-
mittee. Subsequently, an accurate clinical history was taken and all 
patients underwent a complete clinical examination. Before start-
ing chemotherapy, all eligible patients were extensively staged for 
accurate deﬁ nition of disease extension and measurement of dis-
ease with two-view chest X-ray, abdomen ultrasound, computed 
tomography of the involved areas, and bone scan. Complete blood 
cell counts were performed weekly and routine biochemistry at 
 every cycle. After 3 and 6 cycles, patients underwent re-evaluation 
of their disease with the same basal staging procedures. 
 Treatment Schedule 
 Patients received docetaxel 35 mg/m 2  by intravenous infusion 
for 60 min on days 1, 8 and 15, and gemcitabine 800 mg/m 2  by 
intravenous infusion for 30 min after docetaxel infusion on days 1, 
8 and 15. The sequence of 3 administrations on days 1, 8, 15, fol-
lowed by a 2-week rest period, represented a cycle. In order to pre-
vent ﬂ uid retention and hypersensitivity reactions, all patients re-
ceived dexamethasone 8 mg 12 h before administration and on days 
1 and 2. Antiemetic treatment was administered at the discretion 
of each researcher. The routine use of prophylactic G-CSF was not 
allowed; however, investigators were free to employ growth factors 
according to individual patients’ needs in case of neutropenia 
(ANC  ! 900/  l) and/or infectious complications. The type of objec-
tive response achieved and recorded after the ﬁ rst 3 cycles deter-
mined the duration of treatment: in the case of a CR, patients re-
ceived 3 further cycles up to a maximum of 6 cycles of chemother-
apy; in the case of partial tumor regression or stabilization, patients 
received 3 more cycles and were then re-evaluated for response; 
treatment continued up to a total of 8 cycles, progression or unac-
ceptable toxicity. If progression of disease occurred, patients 
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dropped out of the study and were followed up to record overall 
survival. 
 Assessment of Response, Toxicity and Dose Intensity 
 Complete response (CR), partial response (PR), stable disease 
(SD) and progressive disease (PD) were assessed according to the 
WHO criteria  [21] . CR was deﬁ ned as complete regression of all 
lesions and signs and symptoms of disease. PR was deﬁ ned as a 
reduction  6 50% in the sum of the product of the two principal di-
ameters of all measurable lesions, including partial healing of lytic 
lesions or reduction in the number of the uptake areas, lasting at 
least 2 months. SD was considered as a  ! 50% reduction or  ! 25% 
increase in the above sum, lasting at least 3 months. PD was deﬁ ned 
as an increase  1 25% in the sum of the product of the two principal 
diameters of all measurable lesions, and/or the appearance of new 
lesions. Toxicity was assessed at every cycle according to the WHO. 
If, on the planned day of therapy, ANC was  ! 1,500/  l and/or plate-
let count was less than 100,000/  l, chemotherapy was delayed for 
1 week; in the case of slow recovery despite delay, subsequent
doses of both gemcitabine and docetaxel were reduced by 25%. If 
grade 2 liver toxicity occurred, docetaxel and gemcitabine dosages 
were both reduced by 50%; in the case of persistent grade 2 or de 
novo grade 3 hepatic toxicity, treatment was delayed by 1 week to 
allow recovery; if no recovery was veriﬁ ed within 2 weeks, treat-
ment was stopped and patients dropped out. In the case of grade 
1–2 neurotoxicity, the dose of docetaxel was reduced by 50% for 
subsequent administrations, while gemcitabine dosage remained 
unaltered. If neurotoxicity of more than grade 2 occurred, treat-
ment withdrawal was considered. The actual dose intensity was 
calculated for docetaxel and gemcitabine using the following for-
mula: dose (mg)  ! number of administrations/total interval be-
tween courses (weeks). 
 Statistical Analysis 
 The primary end-point of this phase II study was the evaluation 
of clinical efﬁ cacy in terms of clinical response, survival, time to 
progression (TTP) and time to treatment failure (TTF); secondary 
end-points were considered: analysis of toxicity proﬁ le and of dose 
intensity. The study was designed to detect a 60% ORR applying a 
two-step minimax design according to Simon. Considering a type 1 
error of 0.05 and a type 2 error of 0.20, at least 8 objective respons-
es had to be recorded in the ﬁ rst cohort of 16 patients in order to 
proceed to the second step, after which a total of 30 responses had 
to be achieved in the whole population before being able to reject 
the hypothesis that the ORR was less than the estimated 60%. A 
total of 50 assessable patients were to be enrolled in the trial. Dura-
tion of CR was calculated from the ﬁ rst assessment of CR until the 
appearance of PD. Duration of PR or SD was deﬁ ned from the time 
of starting chemotherapy until disease progression. TTP was calcu-
lated from the date of starting chemotherapy until clinical and/or 
instrumental evidence of progressive disease, while overall survival 
was calculated from the date of starting chemotherapy until death 
or last documented follow-up. TTF was calculated from the date of 
starting chemotherapy until the date of progression, death (by any 
cause), adverse event, loss to follow-up, whichever occurred ﬁ rst. 
The follow-up time was measured from the day of the administra-
tion of ﬁ rst the treatment to the last contact or death. 
 All data concerning TTP, TTF and overall survival were ana-
lyzed by computer to generate curves according to the Kaplan and 
Meier method by the SPSS statistical package (version 8.0, 1997). 
 Results 
 Patients’ Characteristics 
 Between January 2001 and June 2003, 58 patients 
with MBC were enrolled into the study. All patients were 
chemotherapy naive for metastatic disease. Fifty-six 
(96.5%) patients were assessable for response and all for 
toxicity. Two patients were not assessable for response 
because they refused to continue therapy. The character-
istics of this cohort of patients are summarized in  table 
1 . The median age was 58.5 years (35–75) and PS accord-
ing to ECOG was 0 in 32 patients (55.2%), 1 in 24 (41.4%), 
2 in 2 (3.4%). Thirty (52%) patients had received an an-
thracycline-based chemotherapy (3 in a neoadjuvant and 
27 in an adjuvant setting). With regard to the other adju-
vant treatments, 2 (3%) patients had received a taxane 
(paclitaxel). In this group, an adequate interval ( 1 12 
months) from the adjuvant treatment, as per protocol, 
was respected. No patient had received previous docetax-
el-containing therapy. Two patients had received adju-
vant high-dose chemotherapy plus peripheral blood stem 
cell reinfusion. Thirty-six (62%) patients had multiple 
sites of disease: 15 (26%) had 2 sites of disease, 21 (36%) 
had  1 3 sites of disease. The sites of metastases were: lung 
in 27 (46%), lymph nodes in 21 (36%), liver in 18 (31%), 
bone in 20 (34%), pleura in 13 (22%), skin in 12 (21%), 
breast in 11 (19%), pericardium in 3 (5%), and perito-
neum, ovary and adrenal gland in 1 (2%). At least 1 vis-
ceral site of metastasis was present in 45 (77.6%) pa-
tients. 
 Response and Survival 
 A total of 270 cycles was administered with a median 
number of 4.5 cycles (1–12) per patient. Planned dose 
intensity for docetaxel was 26.25 mg/m 2 /week and 
600 mg/m 2 /week for gemcitabine. The median actual 
dose intensity for docetaxel was 26.25 (13.12–26.25)
mg/m 2 /week (100% of the planned dose) and 600 (300–
600) mg/m 2 /week (100% of the planned dose) for gem-
citabine. Thirty-eight patients (65%) received treatment 
with a  1 90% dose intensity. 
 Following the research protocol, we proceeded to the 
second step of the study after obtaining 8 objective re-
sponses in the ﬁ rst group of 16 patients. Among the 56 
assessable patients, 9 (16.1%) achieved a CR, 27 (48.2%) 
obtained a PR with an ORR of 64.3%.Twelve (21.4%) 
patients had SD while PD occurred in 8 (14.3%) patients. 
Patients with CR had a median TTP of 12.3 months (95% 
CI: 5.15–19.45); in patients with PR the median TTP was 
15.5 months (95% CI: 9.54–21.46). In patients with SD 
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the median TTP was 9.77 months (95% CI: 2.25–17.28). 
After a median follow-up of 10.6 months, 15 patients died 
(all for tumor-related causes) and 43 patients (74.1%) are 
still alive at the cut-off date of 36 months; 24 patients ex-
perienced PD. The median survival was 22.10 months 
(95% CI: 15.53–28.67). The median survival for patients 
with CR was 22.27 months (95% CI: 13.84–30.70). Pa-
tients who achieved a PR had a median survival of 29.30 
months (95% CI: 18.74–30.61). In patients with SD me-
dian survival was 24.57 months (95% CI: 16.43–32.70). 
The median survival in patients who experienced PD was 
7.43 months (95% CI: 3.96–7.63). Objective response and 
survival data are reported in  table 2 . The Kaplan-Meier 
curve of overall survival is represented in  ﬁ gure 1 . The 
median TTP was 13.6 months (95% CI: 10.71–16.49). 
The median TTF was: 8.60 months (95% CI: 4.79–
12.41). 
 Compliance to Treatment and Toxicity 
 Treatment discontinuation occurred in 2 patients for 
refusal. The most common hematological toxicity was 
neutropenia, which occurred in 28 patients (48.3%) but 
grade 3–4 in only 8 patients (14%). No case of febrile neu-
tropenia was reported. Twenty patients (34.5%) experi-
enced anemia, grade 3 in 2 patients (3.4%). Grade 3 
thrombocytopenia was registered in 4 patients (6.9%). 
Hematological toxicity is reported in  table 3 . 
 Table 1. Patients’ characteristics 
Patient characteristics n %
Number of patients enrolled 58 100
Assessable for activity 56 96
Assessable for toxicity 58 100
Age, median (range) 58.5 (35–75)
Performance status (ECOG)
0 32 55.2
1 24 41.4
2 2 3.4
Histological type
Ductal invasive 40 69
Lobular invasive 7 12.1
Medullary 2 3.4
NOS 9 15.5
Previous treatments
Surgery 49 84
Radiotherapy 15 26
Adjuvant chemotherapy 42 72
Neoadjuvant chemotherapy 3 5
Taxol-containing chemotherapy 2 3
Anthracycline-containing chemotherapy 30 52
High-dose chemotherapy + PBSC 2 3
Hormone therapy adjuvant/ﬁ rst-line 27/6 46/10
Radiotherapy adjuvant/ﬁ rst-line 15/7 26/12
Metastatic sites
1 22 38
2 15 26
 63 21 36
Sites of disease
Lung 27 46
Nodes 21 36
Bone 20 34
Liver 18 31
Pleura 13 22
Skin 12 21
Breast 11 19
Pericardium 3 5
Ovary 1 2
Peritoneum 1 2
Adrenal gland 1 2
Cycles administered
Median (min–max) 4.5 (1–12)
Total 270
 
 
 Table 2. Response and survival 
Objective
response
Patients TTP, months Survival, months
n % median 95% CI median 95% CI
CR 9 16.1 12.3 5.15–19.45 22.27 13.84–30.70
PR 27 48.2 15.5 9.54–21.46 29.30 18.74–30.61
SD 12 21.4 9.77 2.25–17.28 24.57 16.43–32.70
PD 8 14.3 2.7 1.42–3.98  7.43 3.96–7.63
 
 
 Fig. 1. Kaplan-Meier curve of overall survival. The median sur-
vival was 22.10 months (95% CI: 15.53–28.67). 
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 With regard to nonhematological toxicity, alopecia 
was the most common: it occurred in 20 (34.5%) patients, 
but only 5 patients (8.6%) experienced grade 3 alopecia. 
Asthenia was registered in 13 (22.4%) patients but was of 
grade 3 in only 1 case (1.7%). Twelve patients (20.6%) 
experienced nausea/vomiting, mostly of grade 1–2 
(18.9%). Mild hepatic toxicity occurred in 7 patients 
(12%). With respect to grade 3–4 nonhematological tox-
icities, the most frequent were: alopecia as previously cit-
ed, diarrhea in 3 (5%) patients (grade 3 in 2 patients and 
grade 4 in 1 patient) and stomatitis in 2 (4%) cases (grade 
3 in 1 patient and grade 4 in 1 patient). No case of ﬂ uid 
retention syndrome was seen. No patient experienced eye 
tearing toxicity ( table 4 ). There was no treatment-related 
death. The addition of gemcitabine and/or the length of 
treatment did not affect the toxicity proﬁ le. 
 Discussion 
 The difﬁ culties which medical oncologists have in 
ﬁ nding an optimal treatment for MBC, still an incurable 
illness, are witnessed by the large amount of studies per-
formed in this area in which it is necessary to combine 
the need for effective therapies with the goal of the im-
proving quality of life and survival. 
 Docetaxel is a highly active agent in advanced breast 
cancer. It has demonstrated a superior activity when com-
pared both to single agent doxorubicin  [22] or paclitaxel 
 [23] and polichemotherapy as mitomycin C plus vinblas-
tine  [24] or methotrexate plus 5-ﬂ uorouracil  [25] . 
 Although extremely active, the 3-week schedule of 
docetaxel 100 mg/m 2  as single agent is associated with a 
high incidence of myelosuppression  [6] . Weekly admin-
istration of docetaxel has an efﬁ cacy at least comparable 
with the standard 21-day administration with lower my-
elotoxicity  [6–13, 26] . The better toxicity proﬁ le of week-
ly docetaxel makes it particularly suitable for combina-
tion with other active drugs as gemcitabine in MBC pa-
tients. 
 The combination of docetaxel and gemcitabine as ﬁ rst- 
and second-line therapy for MBC has been evaluated in 
phase II trials  [27–36] . Mavroudis et al.  [27] enrolled 52 
patients previously treated for metastatic disease. Their 
patients received gemcitabine 900 mg/m 2  i.v. on days 1 
and 8 and docetaxel 100 mg/m 2  on day 8, every 3 weeks 
and prophylactic G-CSF from the 9th to the 15th day. 
The ORR was 54%, with 14% CR and 40% PR. Four pa-
tients, who had PD after a paclitaxel or docetaxel mono-
therapy, achieved a PR after treatment with the combina-
tion of docetaxel and gemcitabine. The median duration 
of response was 3.6 months and the median TTP 8 
months. Regarding the hematological toxicity, neutrope-
nia of grade 3–4 occurred in 29% of patients despite the 
 Table 3. Hematological toxicity (assessable patients: n = 58) 
Type
(assessable patients = 58)
Grade Patients
n %
Neutropenia G1/G2
G3/G4
20
8
34.5
13.8
Anaemia G1/G2
G3/G4
18
2
31
3.4
Thrombocytopenia G1/G2
G3/G4
19
4
32.7
6.9
 
 
 Table 4. Non-haematological toxicity (assessable patients: n = 58) 
Type Grade Patients
n %
Nausea/vomiting G1/G2
G3/G4
11
1
18.9
1.7
Diarrhea G1/G2
G3/G4
4
3
6.9
5.2
Stomatitis G1/G2
G3/G4
4
2
6.9
3.4
Renal G1/G2
G3/G4
1
–
1.7
–
Hepatic G1/G2
G3/G4
7
–
12.1
–
Alopecia G1/G2
G3/G4
15
5
25.9
8.6
Fever G1/G2
G3/G4
8
–
13.8
–
Cardiac G1/G2
G3/G4
2
–
3.4
–
Neurotoxicity G1/G2
G3/G4
3
1
5.2
1.7
Asthenia G1/G2
G3/G4
12
1
20.7
1.7
Skin G1/G2 (nail changes)
G3/G4
2
1
3.4
1.7
Flu-like syndrome 1 1.7
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prophylactic use of G-CSF and thrombocytopenia of 
grade 3–4 was registered in 21% of patients. The median 
dose intensity was 26.5 and 513 mg/m 2 /week for docetax-
el and gemcitabine, respectively. 
 A regimen of docetaxel and gemcitabine every 2 weeks 
was used as ﬁ rst line therapy in 3 phase II trials. Pelegri 
et al.  [28]  treated 71 patients with docetaxel 65 mg/m 2  
and gemcitabine 2,500 mg/m 2  on day 1 of a 14-day cycle. 
An objective response rate of 66% was registered. Grade 
3–4 neutropenia occurred in 45% of patients. In the study 
of Mavroudis et al.  [27] , 47 patients (37 assessable for 
response) were enrolled to receive docetaxel 65 mg/m 2  
and gemcitabine 1,500 mg/m 2  on day 1 every 2 weeks. 
The intent-to-treat ORR was 75.6%. Grade 3–4 neutro-
penia was registered in 14 (30%) patients with febrile neu-
tropenia in 2 (5%) cases  [29] . Garle et al.  [30]  adminis-
tered docetaxel 65 mg/m 2  and gemcitabine 2,500 mg/m 2  
on day 1 of a 14-day cycle to 48 patients obtaining an ob-
jective response rate of 71%. In this study grade 3–4 neu-
tropenia was also registered in 44% of patients. Grade 
3–4 fatigue (15% of cases) was the most frequent nonhe-
matological toxicity. For comparison with the present 
study, table 5 lists previous studies with the gemcitabine-
docetaxel combination in MBC. 
 In our dose-ﬁ nding study  [19] , 18 heavily pretreated 
patients received 3 escalating weekly doses of docetaxel 
(30, 35 and 40 mg/m 2 ) with a weekly ﬁ xed dose of gem-
citabine 800 mg/m 2  on days 1, 8 and15 of a 28-day cycle. 
The MTD for docetaxel was reached at the 40 mg/m 2  dose 
and the recommended dose for subsequent phase II stud-
ies was established at the 35 mg/m 2  dose. Leucopenia was 
prevalent at the highest dose of 40 mg/m 2 . The promising 
 Table 5. Phase II studies with gemcitabine-docetaxel combination in MBC 
Author and year
of publication
Pa-
tients
Prior therapy Schedule ORR
%
TTP
months
Toxicities, %
Mavroudis et al. [27] 
1999
52 anthracyclines
100%
G 900 mg/m2 1, 8 + T 100 mg/m2
8 q21
54  8 neutropenia G3/4 = 29
thrombocytopenia G3/4 = 21
Fountzilas et al. [31] 
2000
39 anthracyclines
100%
G 1,000 mg/m2  1, 8 + T 75 mg/m2
1 q21
36  7 neutropenia G3/4 = 49
FN = 18
alopecia G3 = 77.5
Laufman et al. [32] 
2001
39 anthracyclines
85%
G 800 mg/m2 1, 8, 15 + T 100 mg/m2 1 
q28
79  7.6 neutropenia G3/4 = 39
FN = 7.7
alopecia = 100
Kornek et al. [33] 
2002
52 anthracyclines
19%
G 1,500 mg/m2 1, 15 + T 50 mg/m2
1, 15 q28
60.5a
43b 
 8.5a
 6.6b
neutropenia G3/4 = 29
alopecia G3 = 35
Garle et al. [30]
2003
48 anthracyclines
33%
G 2,500 mg/m2 1, 14 + T 65 mg/m2
1, 14 q14
71  9.1 neutropenia G3/4 = 44
FN = 4
fatigue G3/4 = 15
Alexopoulos et al.
[34], 2004
50 docetaxel
100%
G 900 mg/m2 1, 8 + T 100 mg/m2
8 q21
46  7.5 neutropenia G3 = 24
Pelegri et al. [28]
2004
71 anthracyclines
28%
G 2,500 mg/m2 1 + T 65 mg/m2
1 q14
66 NR neutropenia G3/4 = 45
Brandi et al. [35]
2004
53 anthracyclines
100%
G 1,000 mg/m2 1, 8 + T 80 mg/m2
8 q21
53  7.5 neutropenia G3/4 = 43
anemia G3/4 = 8
Slee et al. [36]
2004
26 anthracyclines
100% 
G 1,000 mg/m2 1, 8 + T 75 mg/m2
8 q21
61  7.7 leucopenia G3/4 = 23/184 
cycles
Palmeri, present study 58 anthracyclines
52%
G 800 mg/m2 1, 8, 15 + T 35 mg/m2 1, 
8, 15 q28
64.3 13.6 neutropenia G3/4 = 13.8
diarrhea G3/4 = 5.2
G = Gemcitabine; T = docetaxel; NR = not reported; FN = febrile neutropenia.
a First-line treatment.
b Second-line treatment.
 
 
 Palmeri et al.  Oncology 2005;68:438–445 444
activity data obtained (ORR = 58%) in a heavily pre-
treated population of patients, even if small, encouraged 
the exploration of this innovative schedule in a phase II 
setting. 
 The present study focuses on a new combination ther-
apy administered weekly as ﬁ rst line treatment in MBC 
patients. At least 1 visceral site of metastasis was present 
in 45 (77.6%) patients. In the 56 assessable patients, the 
ORR was 64.3% with 9 patients (16.1%) achieving  a CR, 
27 (48.2%) a PR response and 12 (21.4%) patients with 
SD. The median survival was 22.10 months (95% CI: 
15.53–28.67) with 43 (74.1%) patients still alive at the 
cut-off date of 36 months. Noteworthily, the TTP was 
13.6 months (CI 95%: 10.71–16.49). The median TTF 
was: 8.60 months (95% CI: 4.79–12.41). At the time of 
cutting off, 24 patients experienced PD. Another remark-
able point is the length of response in patients with SD: 
in fact, in this subgroup, the median duration of response 
was 19.27 months. Furthermore, the median survival of 
patients who achieved PR was 29.30 months. 
 The data from this study seem to conﬁ rm that the com-
bination of docetaxel and gemcitabine is active in ad-
vanced breast cancer. This weekly schedule seems to be 
active and well tolerated, the median actual dose inten-
sity being 26.25 mg/m 2 /week (100% of the planned dose) 
for docetaxel and 600 mg/m 2 /week (100% of the planned 
dose) for gemcitabine. 
 These results, with 56 assessable patients, are in agree-
ment with other published studies. Grade 3–4 neutrope-
nia occurred in only 8 patients (14%). Regarding nonhe-
matological toxicity, grade 3 alopecia was experienced by 
only 5 cases (9%). No case of ﬂ uid retention syndrome 
was seen. Furthermore, this schedule is manageable in an 
outpatient setting. 
 The need to perform adequately designed and sized 
phase III trials is strongly felt in order to conﬁ rm the 
promising results of this study, considering two study 
populations: patients who have received prior anthracy-
cline-containing therapy and anthracycline-naive pa-
tients. 
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